500 Days Later: Every Step Of Mylan And Upjohn’s Merger Into Viatris
$12bn Deal Aiming For $1bn Of Synergies Launched 16 November
Viatris, the combination of Mylan and Pfizer’s Upjohn unit, launched on 16 November. The culmination of almost 16 months of work, the transaction faced many hurdles, not least the devastating effects of the novel coronavirus pandemic. Generics Bulletin has collated every step of the deal in chronological order, spanning its 476-day history.
You may also be interested in...
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.
Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.
With an eye on moving to market its broad pipeline of innovative brands, Pfizer has cut development of five early-stage biosimilar assets, in a decision that will affect 150 staff. The move is not reflective of Pfizer's overall commitment to biosimilars, the US-based company maintains.